2202:HKEXChemtros Co., Ltd. Analysis
Data as of 2026-06-12 - not real-time
HK$2.64
Latest Price
8/10Risk
Risk Level: High
Executive Summary
China Vanke is trading well beneath its short‑term moving averages, signaling a bearish technical backdrop, while the RSI sits near the neutral zone and the MACD has just turned bullish, offering a marginal short‑term upside signal. Fundamentally, the company is distressed with negative earnings, a severely compressed profit margin, and a debt‑to‑equity ratio that far exceeds industry norms, underscoring substantial balance‑sheet pressure. The DCF model, however, projects a fair value many multiples higher than the current price, suggesting a deep discount if the firm can navigate its financial challenges. Market sentiment is extremely greedy according to the fear‑greed index, yet the stock’s volatility remains elevated and trading volume is on a downtrend, hinting at waning investor interest.
Given the confluence of bearish technical signals, a precarious capital structure, and a massive valuation gap, the near‑term outlook is cautious, while the medium‑ to long‑term perspective hinges on a potential turnaround driven by policy support or asset disposals.
Given the confluence of bearish technical signals, a precarious capital structure, and a massive valuation gap, the near‑term outlook is cautious, while the medium‑ to long‑term perspective hinges on a potential turnaround driven by policy support or asset disposals.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- price below key moving averages
- decreasing trading volume
- high volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- massive valuation discount to DCF fair value
- ongoing debt burden and negative earnings
- potential policy or restructuring support
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- deep undervaluation relative to book and DCF
- possibility of asset sales or strategic turnaround
- long‑term recovery in Chinese real estate sector
Key Metrics & Analysis
Financial Health
Revenue Growth-23.90%
Profit Margin-39.34%
P/E Ratio-1.4
ROE-32.79%
ROA-1.22%
Debt/Equity164.21
P/B Ratio0.2
Op. Cash FlowHK$2.6B
Free Cash FlowHK$39.8B
Industry P/E33.4
Technical Analysis
TrendBearish
RSI40.5
SupportHK$2.48
ResistanceHK$3.16
MA 20HK$2.70
MA 50HK$2.89
MA 200HK$3.87
MACDBullish
VolumeDecreasing
Fear & Greed Index87.3
Valuation
Fair ValueHK$16.74
Target PriceHK$3.61
Upside/Downside36.89%
GradeUndervalued
TypeValue
Risk Assessment
Beta0.00
Volatility40.49%
Sector RiskHigh
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.